Let’s hope it’s the CEO speaking, not the idiot CFO that killed us in the AASLD CC. He talked like a deer under headlights.
At least Emmens has over 200k shares so he better give guidance on how to fight the new competition or how much crap their product/results are and state how much can be anticipated from VRTX other pipelines. If it’s the same PR we’ll go to another new low.
Ian Smith was the sole presenter. He basically rehashed the company line on its product pipeline and insisted that the company is working diligently on an all oral therapy, which he admitted to being the holy grail in HVC treatment.
Other than that, the presentation yielded little else.
Hopefully, Vertex will have a better response to questions of future competition from other hep C drug developers. Ian Smith, the CFO, still has 27,793 shares of VRTX so he should have done a better job at the November 8 conference. Sounds like he was praising Pharmasset. In any case, the CFO is probably the worst choice to explain complicated scientific matters regarding hep C drugs in development. I think it is time for Peter Mueller, Vertex's chief scientific officer, to step up and make the case for why Vertex will remain the leader in the treatment of hep C in the short term and the long term.
We need to hear from the top researchers at Vertex on where Vertex stands versus the coming competition in the Hep C market. And they need to present their position as simply as possible so that even an analyst will understand what they are talking about. The best way to deal with the hype from Pharmasset and Inhibitex is to counter it with scientific facts.